Avidity Biosciences(RNA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track TM Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a potential accelerated approval path for del-brax TM TM Reported positive del-zota data from Phase 1/2 EXPLORE44 trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovati ...